BMS-986165
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Diseases
Conditions
Autoimmune Diseases
Trial Timeline
Apr 4, 2019 → Sep 25, 2019
NCT ID
NCT03956953About BMS-986165
BMS-986165 is a phase 1 stage product being developed by Bristol Myers Squibb for Autoimmune Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03956953. Target conditions include Autoimmune Diseases.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Diseases were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06875960 | Approved | Recruiting |
| NCT04613518 | Phase 2 | Completed |
| NCT04167462 | Phase 3 | Completed |
| NCT03934216 | Phase 2 | Completed |
| NCT03924427 | Phase 3 | Completed |
| NCT03890770 | Phase 1 | Completed |
| NCT03956953 | Phase 1 | Completed |
| NCT03920267 | Phase 2 | Completed |
| NCT03890809 | Phase 1 | Completed |
| NCT03873415 | Phase 1 | Completed |
| NCT03739788 | Phase 1 | Completed |
| NCT03599622 | Phase 2 | Terminated |
| NCT03252587 | Phase 2 | Completed |
| NCT03004768 | Phase 1 | Completed |
Competing Products
20 competing products in Autoimmune Diseases